AZN catalyst calendar

ASTRAZENECA PLC

Upcoming catalysts
30
Cash runway
Cash generating
Cash & investments
$5741M
Phase 3 programs
41

ASTRAZENECA PLC is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics on October 19, 2026. There are 30 upcoming events on record.

ASTRAZENECA PLC generates cash from operations, so a burn-based runway figure does not apply.

Across 377 concluded trials, 90% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 19, 2026 Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics Trial Milestone Phase 4
October 28, 2026 Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy Participants Trial Milestone Phase 1
October 30, 2026 Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease Trial Milestone Phase 4
October 31, 2026 Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients Trial Milestone Phase 4
November 11, 2026 A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment Trial Milestone Phase 1
February 4, 2027 A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234 Trial Milestone Phase 1
February 10, 2027 A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors Trial Milestone Phase 2
April 20, 2027 A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy Trial Milestone Phase 3
May 31, 2027 A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation Trial Milestone Phase 4
June 30, 2027 First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours Trial Milestone Phase 1/Phase 2
July 30, 2027 Volrustomig Priming Regimens Exploratory Phase II Platform Study Trial Milestone Phase 2
August 31, 2027 Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users Trial Milestone Phase 4
November 12, 2027 A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis Trial Milestone Phase 2
November 30, 2027 Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Trial Milestone Phase 2
April 6, 2028 A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus Trial Milestone Phase 3
May 23, 2028 A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin Trial Milestone Phase 3
August 8, 2028 A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight Trial Milestone Phase 3
September 14, 2028 A Phase IIb Study to Evaluate AZD8965 in Participants With IPF. Trial Milestone Phase 2
October 5, 2028 An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants Trial Milestone Phase 3
October 31, 2028 A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma Trial Milestone Phase 2
November 20, 2028 A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer Trial Milestone Phase 3
January 18, 2029 Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer Trial Milestone Phase 1/Phase 2
February 6, 2029 A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM Trial Milestone Phase 2
February 28, 2029 A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer Trial Milestone Phase 3
April 16, 2029 A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer Trial Milestone Phase 1
October 26, 2029 A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event Trial Milestone Phase 3
December 17, 2029 Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin Trial Milestone Phase 3
July 1, 2030 A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD) Trial Milestone Phase 3
September 2, 2030 A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus Trial Milestone Phase 2
March 31, 2033 A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation Trial Milestone Phase 3

Track AZN alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open AZN in the tracker

Recent history

DateEventTypePhase
October 7, 2026 A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES) Trial Milestone Phase 1/Phase 2
October 5, 2026 6-K filed: Foreign issuer report Filing —
October 2, 2026 6-K filed: Corporate announcement Corporate —
October 1, 2026 6-K filed: Foreign issuer report Filing —
October 1, 2026 6-K filed: Foreign issuer report Filing —
September 29, 2026 6-K filed: Foreign issuer report Filing —
September 23, 2026 6-K filed: Foreign issuer report Filing —
September 21, 2026 6-K filed: Clinical or regulatory announcement Filing —
September 21, 2026 6-K filed: Clinical or regulatory announcement Filing —
September 18, 2026 6-K filed: Corporate announcement Corporate —
September 15, 2026 6-K filed: Corporate announcement Corporate —
September 15, 2026 6-K filed: Corporate announcement Corporate —
September 14, 2026 6-K filed: Clinical or regulatory announcement Filing —
September 8, 2026 6-K filed: Foreign issuer report Filing —
September 8, 2026 6-K filed: Foreign issuer report Filing —
September 1, 2026 6-K filed: Foreign issuer report Filing —
September 1, 2026 6-K filed: Corporate announcement Corporate —
September 1, 2026 6-K filed: Corporate announcement Corporate —
September 1, 2026 6-K filed: Foreign issuer report Filing —
September 1, 2026 6-K filed: Corporate announcement Corporate —
September 1, 2026 6-K filed: Foreign issuer report Filing —
September 1, 2026 6-K filed: Foreign issuer report Filing —
August 27, 2026 6-K filed: Clinical or regulatory announcement Filing —
August 25, 2026 6-K filed: Corporate announcement Corporate —
August 19, 2026 6-K filed: Corporate announcement Corporate —
August 17, 2026 6-K filed: Foreign issuer report Filing —
August 17, 2026 6-K filed: Clinical or regulatory announcement Filing —
August 17, 2026 6-K filed: Foreign issuer report Filing —
August 10, 2026 Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy Trial Milestone Phase 2
August 3, 2026 6-K filed: Foreign issuer report Filing —

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.